Summary: Blood samples from 104 patients with clinically suspected thrombophilia were analyzed for coagulation factor V Leiden mutation (1691, G-»A) by allele-specific polymerase chain reaction. In 86 individuals (82.7%), the mutation was not detectable, whereas 15 patients (14.4%) were heterozygous and three patients (2.9%) were homozygous for factor V Leiden mutation. Plasma samples from these individuals were also tested for functional resistance of coagulation factor V to activated protein C (activated protein C resistance). This test was performed on a Schnitger-Gross coagulometer using an activated partial thromboplastin time-based activated protein C resistance test modified by applying a 1 : 5 dilution with factor V-deficiency plasma. All the individuals negative for factor V Leiden mutation were also negative in the functional activated protein C resistance test. On the other hand, all patients carrying the mutation revealed pathologic results in the activated protein C resistance test. The cutoff value for the activated protein C resistance index (> 1.7 = negative) was determined by testing 31 male and female blood donors. One of them was heterozygous for factor V Leiden mutation and had an activated protein C resistance index of 1.4, whereas those without factor V Leiden mutation had an activated protein C resistance index of 1.9 ± 0.1 (χ ± SD). Patients with clinically suspected thrombophilia without factor V Leiden mutation had an activated protein C resistance index of 2.1 ± 0.2 (x ± SD), whereas patients heterozygous for the mutation had an index of 1.5 ± 0.1 (x ± SD). Within the group of patients carrying the mutation, the activated protein C resistance test even distinguished between heterozygous and three homozygous (activated protein C resistance 1.0 to 1.2) carriers. The data demonstrate that the activated protein C resistance test in the presence of factor V-deficiency plasma provides a clear-cut discrimination between normal wildtype and carriers of factor V Leiden mutation with a sensitivity and specificity of 100%. Verification of positive activated protein C resistance tests can be performed easily with a simple and reliable polymerase chain reaction protocol for the 1691, G-»A mutation.
Introduction
Resistance of coagulation factor V to activated protein factor V (factor Va) by activated protein C. It is assumed C is reported to be the most prevalent coagulation abnor-that at least 90% of cases of functional activated protein mality associated with venous thrombosis and embo-C resistance are caused by the factor V Leiden mutation lism. Activated protein C resistance is more prevalent (1) . Heterozygosity for the gene defect is associated with than all other known coagulation abnormalities associ-a 5-to 10-fold higher risk of thrombosis, whereas homoated with venous thrombosis together. It occurs in at zygosity for the mutation seems to be associated with a least 20% of patients with a history of thromboembo-50-to 100-fold increased risk. The risk is further enlism, as well as in the asymptomatic general European hanced by other coagulation abnormalities such as defipopulation, at a prevalence of up to ten percent (1) (2) (3) (4) .
ciency of antithrombin III, protein C or protein S (1, As described by Bertina et al. (4) , the phenotype of acti-5~8 )· Because of cost-to-risk estimations, genotypic vated protein C resistance is associated with a single screening for factor V Leiden in women taking oral conpoint mutation in the coagulation factor V gene at nucle-traceptives has been suggested (9) (10) (11) . otide position 1691 (guanine (G) to adenine (A) substi-Molecular biology based diagnosis of factor V Leiden tution; 1691, G-»A), resulting in the synthesis of a mutation can be achieved by polymerase chain reaction factor V molecule with the substitution of glutamine (Q) analysis, for which many protocols have been described, for arginine (R) at amino acid residue number 506, Determination of activated protein C resistance might be named factor V Q506 or factor V Leiden (4). The conse-used as well, since the mutation results in functional quence of the mutation is loss of an activated protein C activated protein C resistance. However, it has been decleavage site at amino acid residue 506, resulting in an monstrated that the conventional activated partial throminsufficient inactivation of membrane-bound activated boplastin time-based activated protein C resistance assay is influenced by deficiency of coagulation factors, anticoagulatory therapy, lupus anticoagulant and protein S deficiency (12) (13) (14) . As a consequence, the activated protein C resistance test exhibits an unacceptably low sensitivity and specificity for the detection of the mutation. Thus, polymerase chain reaction techniques appeared to be indispensable for screening of factor V Leiden mutation in patients with suspected or manifested thrombophilia, especially when patients are under anticoagulatory therapy (13) .
In order to avoid the influence of coagulation factor or protein S deficiencies, anticoagulation etc. in functional activated protein C resistance tests, some authors used patients' samples upon dilution with factor V deficient plasma (15, 16) . This modification significantly improved sensitivity and specificity of the activated protein C resistance test. As a result, the modified activated protein C-resistance test has been proposed as a screening method in diagnosis of factor V Leiden mutation (15) (16) (17) (18) (19) . On the other hand, it has been shown that the modified test does not clearly discriminate between normal wildtype and homozygous or heterozygous carriers of factor V Leiden mutation in each case (20) . Other groups still use the unmodified activated protein C-resistance test with its low sensitivity and specificity for the detection of factor V Leiden mutation (21, 22) .
We used an activated partial thromboplastin time-based activated protein C-resistance test modified by a 1:5 dilution of plasma samples with factor V deficiency plasma and performed it on a non-automatized Schnitger-Gross coagulometer. It was demonstrated that the modified activated protein C resistance test detects factor V Leiden mutation with a sensitivity and specificity of 100% and even discriminates heterozygous and homozygous forms of the mutation. Verification of the kind of mutation can be restricted to samples with positive activated protein C resistance tests and can be performed easily with the allele-specific polymerase chain reaction protocol used here.
Materials and Methods

Materials
The Chromogenix activated protein C resistance test kit (Coatest) and factor V deficiency plasma were obtained from H mochrom Diagnostika (Essen, Germany). Polymerase chain reaction primers and dNTPs were purchased from Pharmacia (Freiburg, Germany). Proteinase K was supplied by Sigma (Munich, Germany). Taq polymerase was purchased from Gibco (Karlsruhe, Germany). All other chemicals were analytical or molecular biological grade and obtained from commercial sources.
Study population and blood sampling
Citrated plasma samples (venous blood : 0.1 mol/1 sodium citrate = 10:1) were obtained from male and female patients with clinically suspected thrombophilia referred to our laboratory, or from male and female blood donors for determination of reference values. Platelet-poor plasma was obtained by two centrifugation steps of 10 min each at 2000 g at room temperature. The plasma was collected carefully, strictly avoiding contamination with platelets. Aliquots were frozen at -25 °C.
Activated protein C resistance test
Plasma samples were thawed immediately before testing by incubation at 37 °C for exactly 10 min. Each sample was prediluted with factor V deficiency plasma (1 : 5) to exclude effects of other factors than factor V Leiden mutation on the activated protein C resistance test. Diluted plasma samples (100 μΐ) were mixed with 100 μΐ prewarmed activated partial thromboplastin time reagent and incubated for 5 min at 37 °C. Coagulation on a SchnitgerGross coagulometer (Amelung, Lemgo, Germany) was started by adding either 100 μΐ CaCl 2 (0.025 mol/1) or a mixture of activated protein C and CaCl 2 . The results were expressed as a ratio of the coagulation time obtained with the CaCl 2 -activated protein C mixture over CaCl 2 without activated protein C (activated protein C resistance index).
DNA preparation and identification of the 1691, G-»A mutation in the factor V gene Genomic DNA was prepared from peripheral blood leukocytes by a standard procedure. In brief, cells were lysed by mixing 100 μΐ EDTA-blood samples with 500 μΐ Tris/EDTA buffer (10 mmol/1 Tris-HCl, pH 8.0 and 1 mmol/1 EDTA). The nuclei were pelleted by centrifugation for 10 s at 13 000 g. Supernatants were decanted and the procedure was repeated one to two times until clean nuclei pellets were obtained. The pellets were resuspended in 100 μΐ lysis buffer containing 10 mmol/1 Tris-HCl, pH 8.3, 50 mmol/1 KC1, 1.5 mmol/1 MgCl 2 , 0.1 g/1 gelatin and 5 g/1 Tween 20. After adding 10 μΐ proteinase Κ (10 g/1), the samples were incubated for 45 min at 56 °C followed by incubation for 10 min at 95 °C to inactivate proteinase K. DNA samples were stored at -25 °C.
Allele-specific polymerase chain reaction was performed using primers recently described (2, 23): Factor V FOR2 (5* consensus primer): 5' AGGAACAACAACATGATC 3'; Factor V NOR: 5' GGACAAAATACCTGTATTCCAC 3'; Factor V MUT: 5' GGA-CAAAATACCTGTATTCCAT 3'. Duplicate samples of genomic DNA from each individual were subjected to polymerase chain reaction with either the Factor V FOR2/Factor V NOR primer set specific for the "G" (normal) allele or the Factor V FOR2/Factor V MUT primer set specific for the "A" (mutant) allele. The specificity of the allele-specific primers was extremely high by incorporation of an additional mismatch at the penultimate position (23) . 
Results
Reference values for the modified activated protein C resistance test
Determination of reference values for the activated protein C resistance index was performed by testing 31 blood donors between the ages of 20 to 64 years, approximately corresponding to the ages of patients in the study. The 30 individuals without factor V Leiden muta-tion had indices between 1.7 and 2.1 (fig. 2a) . The mean value (x) of the activated protein C resistance index was 1.9, the standard deviation (SD) was 0.1. The cutoff value determined as χ -2 SD was 1.7. None of the blood donors without factor V Leiden mutation had an activated protein C resistance index lower than 1.7. One blood donor had an index of 1.4 and the genotype was heterozygous for the mutation.
Comparison of the genotype test for factor V Leiden mutation with the modified functional test for activated protein C resistance Blood samples from 104 patients with clinically suspected thrombophilia were tested for factor V Leiden mutation by allele-specific polymerase chain reaction. Definite signals were obtained in the DNA of homozygous normal patients as well as in patients heterozygous or homozygous for factor V Leiden ( fig. 1 ). Eighty-six individuals (82.7%) were normal, 15 (14.4%) were heterozygous and three individuals (2.9%) were homozygous for factor V Leiden ( fig. 2b ). Selecting the patients by the criterium "clinically manifested thrombosis", factor V Leiden mutation was detected in 32% of the individuals.
Using the modified activated protein C resistance test as described in Materials and Methods and the cutoff value of the activated protein C resistance index of 1.7, all patients without factor V Leiden were detected as normal in an index range between 1.7 and 2.5 with a mean Polymerase chain reaction was performed using specific pairs of primers for amplification of either the normal (wildtype) allele or of the mutant allele of factor V. Amplification products (224 base pairs) we stained by ethidium bromide. Tracks are as follows: 1 and 10: 100 base pairs ladder; 2 and 3: wildtype and mutation amplification of an individual without factor V Leiden mutation; 4 and 5: wildtype and mutation amplification of a heterozygous patient; 6 and 7: wildtype and mutation amplification of a homozygous carrier of factor Leiden mutation; 8 and 9: wildtype and mutation amplification of reagent controls without genomic DNA.
Markers indicate the position of the specific 224 base pair amplification products. One of two identical polymerase chain reaction assays is shown. Activated protein C resistance index Activated protein C resistance index value of 2.1 (SD = 0.2). Patients heterozygous for factor V Leiden had indices between 1.3 and 1.6 with a mean value of 1.5 (SD = 0.1), whereas the three patients found homozygous for the mutation had activated protein C resistance indices of 1.0 and 1.2 ( fig. 2b) . One of these patients with an index of 1.2 suffered from acute lung embolism and therefore was under therapy with heparin when citrated blood samples were taken for the activated protein C resistance test.
Discussion
Venous thrombosis occurs with a prevalence of 1/1000 individuals. The major reason for genetically determined thrombosis is resistance of coagulation factor V to activated protein C (activated protein C resistance), which is found in 20-60% of patients with venous thrombosis (1) . At least 90% of cases of functional activated protein C resistance are caused by a single point mutation in the factor V gene named factor V Leiden (1, 4) . We found activated protein C resistance/factor V Leiden in 17% of patients with suspected thrombophilia and in 32% of those with clinically manifested thromboembolic events.
This is in line with the frequencies of factor V Leiden mutation reported by others (1-4) . Patients homozygous for factor V Leiden mutation have also been shown to have a higher recurrence rate for thrombosis as compared with a control population (24) . Thus, it seems to be indispensable for medical laboratories to offer tests for screening and verification of activated protein C resistance/factor V Leiden.
A definite method for detecting the mutation is the polymerase chain reaction. However, some protocols published so far are troublesome and can lead to equivocal results. On the other hand, testing of activated protein C resistance lacks specificity and sensitivity when using the conventional assay (14, 21, 22) . Whether the activated protein C resistance test in samples diluted with factor V deficient plasma provides clear-cut discrimination between normal wildtype and carriers of factor V Leiden mutation is still matter of debate (15) (16) (17) (18) (19) (20) .
We adapted the activated partial thromboplastin timebased activated protein C resistance test with factor V deficient plasma dilution to a Schnitger-Gross coagulometer and were able to detect factor V Leiden mutation with a sensitivity and specificity of 100% in 104 patients and 31 blood donors. This is consistent with recent reports showing similar results from studies performed on fully automated coagulation systems that are not available in each medical laboratory (17, 18) . In these studies the cutoff values for activated protein C resistance indices were between 2 and 2.5, whereas we found a cutoff value of 1.7 (determined by testing blood donors without the mutation) clearly discriminating patients without the mutation from heterozygous patients. Thus, it seems to be necessary that each laboratory determines its reference values for the activated protein C resistance index that refer to the analytical system and to the individual protocol used. The fact that in other hands the modified activated protein C resistance test did not discriminate in each case (20) might depend on a lack of exact assay standardization, as was also observed in our hands when evaluating the test (not shown). Therefore, it might be useful to verify positive or questionable results of the activated protein C resistance test, especially in the phase of test evaluation. The allele-specific polymerase chain reaction protocol described here proved to be reliable and easy to perform.
In the present study, a cutoff value for the activated protein C resistance index of 1.3 discriminated heterozygous from homozygous carriers of the mutation. However, the number of three individuals homozygous for factor V Leiden mutation was too small to allow a fundamental statement. The mean value of the activated protein C resistance index of blood donors without factor V Leiden was 1.9, whereas the mean value in patients without carrying the mutation was 2.1. The difference in mean values might be due to the fact that in contrast to healthy blood donors, the hospitalized patients were suffering from various diseases and as a rule were under drug treatment. Despite this, the cutoff determined by testing blood donors also strictly discriminated patients with or without the mutation.
It has been reported that the activated protein C resistance test with factor V deficient plasma is even valid in patients with oral anticoagulation or parenteral heparin therapy (15-17, 19, 25) . This is in line with our observation that one patient with intravenous application of heparin was detected accurately to be homozygous for factor V Leiden by the modified activated protein C resistance test.
